RadNet Reports Third Quarter Financial Results Demonstrating Strong Recovery from the COVID-19 Impact
11/09/2020 - 06:00 AM
Indicating a substantial recovery from the impact of COVID-19, Total Net Revenue (“Revenue”) was $291.8 million in the third quarter of 2020, a sequential increase of 53.1% from the second quarter of 2020 and a decrease of only 0.3% from last year’s third quarter of $292.7 million As a result of aggressive cost containment measures, Adjusted EBITDA(1) was $45.8 million in the third quarter of 2020, a sequential increase of 102.8% from the second quarter of 2020 and an increase of 11.7% from last year’s third quarter Adjusted EBITDA(1) of $41.0 million Adjusted EBITDA(1) margin was 15.7% during the quarter as compared to 14.0% in last year’s third quarter, an increase of 169 basis points (1.7% ) Adjusting for the non-cash impact from the Company’s interest rate hedges on Net Income (“Adjusted Net Income”), Adjusted Net Income Per Share was $0.15 in this year’s third quarter, as compared to Adjusted Net Loss Per share of $(0.16) in the second quarter of this year and Net Income Per Share of $0.06 in last year’s third quarter; this is a sequential increase of $0.31 per share from the second quarter of 2020 and $0.09 per share from last year’s third quarter Aggregate procedural volumes increased 66.2% from the second quarter of 2020 At third quarter end, RadNet had a cash balance of $89.7 million and was undrawn on its $195 million revolving line of credit Subsequent to quarter end, RadNet announced the formation of a joint venture with Adventist Health in Simi Valley, California and the creation of a new operating platform in Phoenix, Arizona with Dignity Health/CommonSpirit Health LOS ANGELES, Nov. 09, 2020 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 334 owned and/or operated outpatient imaging centers, today reported financial results for its third quarter of 2020.
Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, “I am very pleased with our performance during the quarter. Our sequential improvement from the second quarter of 2020 is illustrative of both a strong recovery of our procedural volumes and our focus on controlling costs. Compared to the second quarter of this year, our Revenue grew 53.1% and our aggregate procedural volumes increased 66.2% . Our Adjusted EBITDA increased 102.8% from the second quarter, and our Adjusted Net Income Per Share increased by $0.31, reversing an Adjusted Net Loss Per Share in the second quarter of $(0.16). Our Adjusted EBITDA margin increased by 169 basis points (1.7% ) from last year’s third quarter. The improvement in Adjusted EBITDA, Adjusted EBITDA margin and Net Income Per Share as compared to the second quarter is even more notable since this year’s second quarter results were aided by $25.5 million of funds we received and recognized as income under the CARES Act Provider Relief Fund. This quarter, we received only $221,000 of Cares Act funds.”
Dr. Berger continued, “COVID-19 necessitated that we evaluate every part of our business to reduce expenses and conserve cash. In addition to staffing, we addressed costs associated with purchasing, pre-authorization, scheduling, revenue cycle management, equipment service, facility rent, insurance and center-level operating protocols. The adjustments we made over the last six months have materially improved how we are delivering our services and have significantly increased operating margins. These enhancements should favorably contribute to our performance in the coming quarters, as increasing procedural volumes are anticipated if our country continues to recover from COVID-19.”
Dr. Berger added, “During the COVID-19 period, we temporarily closed facilities, suspended certain modalities at some facilities which remained open, consolidated patient volume into the centers of excellence, negotiated and restructured agreements with vendors and landlords and reduced employee costs through furloughs and temporary salary cuts, among other actions. Not only did these actions prove to secure our business in this difficult period, but they resulted in enhanced liquidity. We completed the third quarter with a cash balance of $89.7 million , and we remain undrawn on our $195 million revolving line of credit. I am also pleased to report that, as of August 1st , we began bringing back substantially all of our employees from furloughs and restored the wages of those team members who took pay reductions as a result of COVID-19. This process was completed as of October 1st .”
“In October, we announced two partnerships that should further our strategic growth. First, we partnered with Adventist Health to create an outpatient imaging joint venture in Simi Valley, California to initially include three multimodality facilities and the management of the Nancy Reagan Breast Center. This affiliation with Adventist Health, one of the largest health systems on the West Coast and Hawaii, is scheduled to begin operations in January. Second, we created an operating platform in Phoenix, Arizona through a partnership with Dignity Health/CommonSpirit Health. Though this is our third partnership with Dignity, it is RadNet’s first entry into a new geography since we entered the New York City marketplace in 2013. We initially acquired eight Arizona facilities and, with Dignity, are committed to substantially growing the scope and breadth of this platform. Dignity will bring great value to the newly created partnership through its ownership of hospitals, medical groups and urgent care centers and its broad affiliations and relationships with physician practices in the Phoenix healthcare delivery system,” concluded Dr. Berger.
Third Quarter Financial Results
For the third quarter of 2020, RadNet reported Revenue of $291.8 million , Adjusted EBITDA(1) of $45.8 million and Net Income of $6.2 million . Compared to the second quarter of this year, Revenue increased $101.2 million (or 53.1% ) and Adjusted EBITDA(1) increased $23.2 million (or 102.8% ). Revenue decreased $916,000 (or 0.3% ) and Adjusted EBITDA(1) increased $4.8 million (or 11.7% ) from last year’s same quarter.
Net Income increased $3.0 million compared to the third quarter of 2019 and increased $16.8 million from the second quarter of 2020. Net Income Per Share for the third quarter of 2020 was $0.12, compared to Net Income Per Share in the third quarter of 2019 of $0.06 (based upon a weighted average number of diluted shares outstanding of 52.0 million in 2020 and 50.4 million in 2019). Adjusting for the non-cash impact of the Company’s interest rate hedges in this year’s third quarter, Adjusted Net Income Per Share was $0.15. This compares to Adjusted Net Loss Per Share of $(0.16) in the second quarter of 2020.
Affecting Net Income in the third quarter of 2020 were certain non-cash expenses or non-recurring items including: $2.1 million of non-cash employee stock compensation expense resulting from the vesting of certain options and restricted stock; $571,000 of severance paid in connection with headcount reductions related to cost savings initiatives; $342,000 loss on the sale or disposal of certain capital equipment; $2.0 million of non-cash impact from interest rate hedges; and $1.1 million of amortization of deferred financing costs, other non-cash interest and loan discounts related to our credit facilities.
For the third quarter of 2020, as compared to the prior year’s third quarter, MRI volume decreased 6.1% , CT volume was flat and PET/CT volume increased 0.4% . Overall volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, decreased 5.7% from the prior year’s third quarter. On a same-center basis, including only those centers which were part of RadNet for both the third quarters of 2020 and 2019, MRI volume decreased 5.8% , CT volume decreased 0.9% and PET/CT volume increased 2.3% . Overall same-center volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, decreased 5.6% compared to the prior year’s same quarter.
Nine Month Financial Results
For the nine months ended September 30, 2020, RadNet reported Revenue of $763.9 million , Adjusted EBITDA(1) of $88.8 million and Net Loss of $20.8 million . Revenue decreased $89.4 million (or 10.5% ), Adjusted EBITDA(1) decreased $28.5 million (or 24.3% ) and Net Income decreased $25.2 million from the first nine months of 2019. Net Loss Per Share for the nine month period ended September 30, 2020 was $(0.41), compared to Net Income Per Share of $0.09 in corresponding nine month period of 2019 (based upon a weighted average number of fully diluted shares outstanding of 50.7 million in 2020 and 50.1 million in 2019). Adjusting for the non-cash impact of the Company’s interest rate hedges, Adjusted Net Loss Per Share was $(0.31) for the nine month period of 2020.
Affecting operating results in the nine months ended September 30, 2020 were certain non-cash expenses or non-recurring items including: $10.1 million of non-cash employee stock compensation expense resulting from the vesting of certain options and restricted stock; $1.6 million of severance paid in connection with headcount reductions related to cost savings initiatives; $543,000 loss on the sale or disposal of certain capital equipment; $6.7 million of non-cash impact from interest rate hedges; and $3.3 million of amortization of deferred financing costs, other non-cash interest and loan discounts related to our credit facilities.
Conference Call for Today
Dr. Howard Berger, President and Chief Executive Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call to discuss its third quarter 2020 results on Monday, November 9th, 2020 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).
Conference Call Details:
Date: Monday, November 9, 2020
It is recommended that participants dial in approximately 5 to 10 minutes prior to the start of the 10:30 a.m. call. There will also be simultaneous and archived webcasts available at http://public.viavid.com/index.php?id=142324
About RadNet, Inc.
RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 334 owned and/or operated outpatient imaging centers. RadNet's core markets include California, Maryland, Delaware, New Jersey, New York and Arizona. In addition, RadNet provides radiology information technology solutions, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total of approximately 8,600 employees. For more information, visit http://www.radnet.com .
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are expressions of our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Forward-looking statements in this press release include, among others, statements we make regarding response to and the expected future impacts of COVID-19, including statements about our anticipated business results, balance sheet and liquidity and our future liquidity, burn rate and our continuing ability to service or refinance our current indebtedness.
Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following:
the ongoing impact of the COVID-19 pandemic on our business, suppliers, payors, customers, referral sources, partners, patients and employees, including (i) government’s unprecedented action regarding existing and potential restrictions and/or obligations related to citizen and business activity to contain the virus; (ii) the consequences of an economic downturn resulting from the impacts of COVID-19 and the possibility of a global economic recession; (iii) the impact of the volume of canceled or rescheduled procedures, whether as a result of government action or patient choice; (iv) measures we are taking to respond to the COVID-19 pandemic, including changes to business practices; (v) the impact of government and administrative regulation, guidance and appropriations; (vi) changes in our revenues due to declining patient procedure volumes, changes in payor mix; (vii) potential increased expenses or workforce disruptions related to our employees that could lead to unavailability of key personnel; (viii) workforce disruptions related to our key partners, suppliers, vendors and others we do business with; (ix) the impact of return to work orders in certain states in which we operate; and (x) increased credit and collectability risks; the availability and terms of capital to fund our business; our ability to service our indebtedness, make principal and interest payments as those payments become due and remain in compliance with applicable debt covenants, in addition to our ability to refinance such indebtedness on acceptable terms; changes in general economic conditions nationally and regionally in the markets in which we operate; the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities; our ability to maintain our current credit rating and the impact on our funding costs and competitive position if we do not do so; volatility in interest and exchange rates, or credit markets; the adequacy of our cash flow and earnings to fund our current and future operations; changes in service mix, revenue mix and procedure volumes; delays in receiving payments for services provided; increased bankruptcies among our partner physicians or joint venture partners; the impact of the political environment and related developments on the current healthcare marketplace and on our business, including with respect to the future of the Affordable Care Act; the extent to which the ongoing implementation of healthcare reform, or changes in or new legislation, regulations or guidance, enforcement thereof by federal and state regulators or related litigation result in a reduction in coverage or reimbursement rates for our services, or other material impacts to our business; closures or slowdowns and changes in labor costs and labor difficulties, including stoppages affecting either our operations or our suppliers' abilities to deliver supplies needed in our facilities; the occurrence of hostilities, political instability or catastrophic events; the emergence or reemergence of and effects related to future pandemics, epidemics and infectious diseases; and noncompliance by us with any privacy or security laws or any cybersecurity incident or other security breach by us or a third party involving the misappropriation, loss or other unauthorized use or disclosure of confidential information. Any forward-looking statement contained in this current report is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that we may make from time to time, whether as a result of changed circumstances, new information, future developments or otherwise, except as required by applicable law.
Regulation G: GAAP and Non-GAAP Financial Information
This release contains certain financial information not reported in accordance with GAAP. The Company uses both GAAP and non-GAAP metrics to measure its financial results. The Company believes that, in addition to GAAP metrics, these non-GAAP metrics assist the Company in measuring its cash-based performance. The Company believes this information is useful to investors and other interested parties because it removes unusual and nonrecurring charges that occur in the affected period and provides a basis for measuring the Company's financial condition against other quarters. Such information should not be considered as a substitute for any measures calculated in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Reconciliation of this information to the most comparable GAAP measures is included in this release in the tables which follow.
CONTACTS: RadNet, Inc. Mark Stolper, 310-445-2800 Executive Vice President and Chief Financial Officer
RADNET , INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA) September 30, 2020 December 31, 2020 (unaudited) ASSETS CURRENT ASSETS Cash and cash equivalents $ 89,739 $ 40,165 Accounts receivable 137,411 154,763 Due from affiliates 424 1,242 Prepaid expenses and other current assets 31,482 45,004 Total current assets 259,056 241,174 PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS Property and equipment, net 361,950 367,795 Operating lease right-of-use assets 451,613 445,477 Total property, equipment and right-of-use assets 813,563 813,272 OTHER ASSETS Goodwill 470,685 441,973 Other intangible assets 57,152 42,994 Deferred financing costs 1,944 1,559 Investment in joint ventures 35,571 34,470 Deferred tax assets, net of current portion 42,188 34,548 Deposits and other 37,707 36,996 Total assets $ 1,717,866 $ 1,646,986 LIABILITIES AND EQUITY CURRENT LIABILITIES Accounts payable, accrued expenses and other $ 205,701 $ 207,585 Due to affiliates 12,287 14,347 Deferred revenue 45,846 1,316 Current finance lease liability 3,041 3,283 Current operating lease liability 67,449 61,206 Current portion of notes payable 39,463 39,691 Total current liabilities 373,787 327,428 LONG-TERM LIABILITIES Long-term finance lease liability 1,108 3,264 Long-term operating lease liability 428,233 420,922 Notes payable, net of current portion 627,179 652,704 Other non-current liabilities 41,438 9,529 Total liabilities 1,471,745 1,413,847 EQUITY Common stock - $.0001 par value, 200,000,000 shares authorized; 51,596,098 and 50,314,328 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively 5 5 Additional paid-in-capital 306,079 262,865 Accumulated other comprehensive loss (24,923 ) (8,026 ) Accumulated deficit (123,956 ) (103,159 ) Total RadNet, Inc.'s stockholders' equity 157,205 151,685 Noncontrolling interests 88,916 81,454 Total equity 246,121 233,139 Total liabilities and equity $ 1,717,866 $ 1,646,986
RADNET, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA) (unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 REVENUE Service fee revenue $ 256,730 $ 261,908 $ 660,760 762,751 Revenue under capitation arrangements 35,046 30,784 103,145 90,587 Total service revenue 291,776 292,692 763,905 853,338 Provider relief funding 221 - 25,696 - OPERATING EXPENSES Cost of operations, excluding depreciation and amortization 246,462 254,383 708,095 743,997 Depreciation and amortization 21,247 20,490 64,536 60,193 Loss on sale and disposal of equipment and other 342 917 543 1,990 Severance costs 571 52 1,647 1,054 Total operating expenses 268,622 275,842 774,821 807,234 INCOME FROM OPERATIONS 23,375 16,850 14,780 46,104 OTHER INCOME AND EXPENSES Interest expense 11,061 11,895 33,443 36,589 Equity in earnings of joint ventures (2,276 ) (1,955 ) (5,176 ) (6,072 ) Non-cash change in fair value of interest rate hedge 679 - 4,523 - Other (income) expenses (139 ) 2 (247 ) 1,271 Total other expenses 9,325 9,942 32,543 31,788 INCOME (LOSS) BEFORE INCOME TAXES 14,050 6,908 (17,763 ) 14,316 (Provision for) benefit from income taxes (3,825 ) (1,816 ) 5,029 (3,556 ) NET INCOME (LOSS) 10,225 5,092 (12,734 ) 10,760 Net income attributable to noncontrolling interests 4,069 1,897 8,063 6,400 NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS $ 6,156 $ 3,195 $ (20,797 ) $ 4,360 BASIC NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS $ 0.12 $ 0.06 $ (0.41 ) $ 0.09 DILUTED NET INCOME (LOSS) PER SHARE ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS $ 0.12 $ 0.06 $ (0.41 ) $ 0.09 WEIGHTED AVERAGE SHARES OUTSTANDING Basic 51,358,603 49,807,460 50,746,380 49,597,138 Diluted 51,955,815 50,360,360 50,746,380 50,113,306
RADNET, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASHFLOWS (IN THOUSANDS) (unaudited) Nine Months Ended September 30, 2020 2019 CASH FLOWS FROM OPERATING ACTIVITIES Net (loss) income $ (12,734 ) $ 10,760 Adjustments to reconcile net (loss) income to net cash provided by operating activities: Depreciation and amortization 64,536 60,193 Amortization of operating lease assets 50,769 49,948 Equity in earnings of joint ventures,net of dividends 530 (2,148 ) Amortization deferred financing costs and loan discount 3,266 3,103 Loss on sale and disposal of equipment and other 543 1,990 Amortization of cash flow hedge, net of taxes 1,861 - Non-cash change in fair value of interest rate hedge 4,523 - Stock-based compensation 10,144 6,963 Other noncash item included in cost of operations - (559 ) Change in fair value of contingent consideration (145 ) (1,749 ) Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions: Accounts receivable 17,380 (3,467 ) Other current assets 13,522 (1,569 ) Other assets (700 ) (5,770 ) Deferred taxes (7,640 ) (4,230 ) Operating leases (43,351 ) (49,721 ) Deferred revenue 44,530 (490 ) Accounts payable, accrued expenses and other 23,309 19,349 Net cash provided by operating activities 170,343 82,603 CASH FLOWS FROM INVESTING ACTIVITIES Purchase of imaging facilities and other acquisitions (10,125 ) (27,150 ) Equity investments at fair value - (143 ) Purchase of property and equipment (77,303 ) (68,269 ) Proceeds from sale of equipment 779 760 Proceeds from sale of equity interests in a joint venture - 132 Nulogix return of capital - 792 Equity contributions in existing joint ventures (1,631 ) (103 ) Net cash used in investing activities (88,280 ) (93,981 ) CASH FLOWS FROM FINANCING ACTIVITIES Principal payments on notes and leases payable (2,704 ) (4,778 ) Payments on Term Loan Debt (32,472 ) (29,918 ) Additional deferred finance costs on revolving loan amendment (741 ) - Proceeds from issuance of new debt, net of issuing costs - 97,144 Proceeds from Payment Protection Program 4,023 - Distributions paid to noncontrolling interests (601 ) (1,818 ) Proceeds from sale of noncontrolling interest - 5,275 Contribution from a noncontrolling partners - 750 Proceeds from revolving credit facility 250,900 251,200 Payments on revolving credit facility (250,900 ) (279,200 ) Proceeds from issuance of common stock upon exercise of options - 50 Net cash (used in) provided by financing activities (32,495 ) 38,705 EFFECT OF EXCHANGE RATE CHANGES ON CASH 6 (28 ) NET INCREASE IN CASH AND CASH EQUIVALENTS 49,574 27,299 CASH AND CASH EQUIVALENTS, beginning of period 40,165 10,389 CASH AND CASH EQUIVALENTS, end of period $ 89,739 $ 37,688 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash paid during the period for interest $ 31,210 $ 36,058
RECONCILIATION OF GAAP NET INCOME (LOSS) ATTRIBUTABLE TO RADNET, INC. COMMON SHAREHOLDERS TO ADJUSTED EBITDA(1) (IN THOUSANDS)
Three Months Ended September 30, 2020 2019 Net Income Attributable to RadNet, Inc. Common Shareholders $ 6,156 $ 3,195 Plus Interest Expense 11,061 11,895 Plus Provision for Income Taxes 3,825 1,816 Plus Depreciation and Amortization 21,247 20,490 Plus Loss on Sale of Equipment 342 917 Plus Severance Costs 571 52 Plus Non-cash Change in Fair Value of Interest Rate Hedge 679 - Plus Other (Gains) Expenses (139 ) 2 Plus Non-Cash Employee Stock-Based Compensation 2,067 1,381 Plus Legal Settlements 1,248 Adjusted EBITDA ( 1) $ 45,809 $ 40,996 Nine Months Ended September 30, 2020 2019 Net (Loss) Income Attributable to RadNet, Inc. Common Shareholders $ (20,797 ) $ 4,360 Plus Interest Expense 33,443 36,589 Plus (Benefit From) Provision for Income Taxes (5,029 ) 3,557 Plus Depreciation and Amortization 64,536 60,193 Plus Loss on Sale of Equipment 543 1,989 Plus Severance Costs 1,647 1,054 Plus Non-cash Change in Fair Value of Interest Rate Hedge 4,523 - Plus Other (Gains) Expenses (247 ) 1,271 Plus Non-Cash Employee Stock-Based Compensation 10,144 6,964 Plus Legal Settlements - 1,248 Adjusted EBITDA ( 1) $ 88,763 $ 117,225
PAYOR CLASS BREAKDOWN Third Quarter 2020 Commercial Insurance/Other Patient Revenue 57.9 % Medicare 21.5 % Capitation 12.0 % Workers Compensation/Personal Injury 2.5 % Medicaid 2.4 % Other/Non Patient 3.7 % Total 100.0 %
RADNET PAYMENTS BY MODALITY Third Quarter Full Year Full Year Full Year 2020 2019 2018 2017 MRI 35.1 % 35.8 % 35.2 % 34.9 % CT 17.3 % 16.9 % 16.5 % 16.2 % PET/CT 5.8 % 5.6 % 5.7 % 5.2 % X-ray 7.2 % 8.1 % 8.4 % 8.9 % Ultrasound 12.4 % 12.4 % 12.2 % 12.1 % Mammography 16.5 % 15.2 % 15.8 % 16.3 % Nuclear Medicine 0.9 % 1.0 % 1.1 % 1.1 % Other 4.7 % 4.9 % 5.1 % 5.2 % 100.0 % 100.0 % 100.0 % 100.0 %
(1) The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations and adjusted for losses or gains on the sale of equipment, other income or loss, transaction expenses, debt extinguishments and non-cash equity compensation. Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non-controlling interests in subsidiaries, and is adjusted for non-cash or extraordinary and one-time events taken place during the period.
Adjusted EBITDA is reconciled to its nearest comparable GAAP financial measure. Adjusted EBITDA is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare industry to assess business performance, and is a measure of leverage capacity and ability to service debt. Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.
